Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

ClinicalTrials.gov ID: NCT01281631

Public ClinicalTrials.gov record NCT01281631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Study identification

NCT ID
NCT01281631
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Enrollment
136 participants

Conditions and interventions

Interventions

  • NP001 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
21 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012
Last update posted
Nov 21, 2012

2011 – 2012

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Mayo Clinic, Scottsdale Scottsdale Arizona 85259
UC, Irvine Irvine California 92868-4281
UCLA Los Angeles California 90095
California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center San Francisco California 94115
Mayo Clinic, Jacksonville Jacksonville Florida 32224
The Emory Clinic Atlanta Georgia 30322
University of Kansas Medical Center, Landon Center on Aging Kansas City Kansas 66160
University of Kentucky, Department of Neurology Lexington Kentucky 40536-0284
Massachusetts General Hospital Charlestown Massachusetts 02129
Columbia University New York New York 10032
SUNY Upstate Medical University, Syracuse Syracuse New York 13210
Carolinas Medical Center Charlotte North Carolina 28207
Duke University, Dept of Neurology Durham North Carolina 27705
Cleveland Clinic Cleveland Ohio 44195
Providence ALS Center Portland Oregon 97213
Methodist Hospital Research Institute, Methodist Neurologic Institute Houston Texas 77030
Providence Saint Peter Hospital Centralia Washington 98531

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01281631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 21, 2012 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01281631 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →